Related Experiment Video
Updated: Feb 16, 2026
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
Published on: June 7, 2016
microRNA as a systemic intervention in the specific breast cancer subtypes with C-MYC impacts; introducing
Vida Pourteimoor1, Mahdi Paryan2, Samira Mohammadi-Yeganeh3,4
1Biochemistry Department, University of Zanjan, Zanjan, Iran.
Abstract:
Breast cancer is indisputably a heterogeneous disease, in which a formidable combination of definitely dis-regulated C-MYC and microRNA (miRNA) profiles along with other factors are responsible to generate a specific type of breast cancer. C-MYC as a master regulator of more than 20,000 genes can modify the expression of genes underlying to perform diverse conflicting functional frameworks. The functional spectra of miRNA in the new areas of the evolution of cell behaviors are identified. Here, we endeavor to summarize some recent advances of miRNA applications that can be recruited as combinatorial targeted therapy for patients with breast cancer. Also, it is important to indicate that some exosomal miRNAs including miR-126, miR-122, miR-92-1, miR-19a, and miR-29c together with circular miRNAs, such as miR-21-5p, miR-96-5p, and miR-125b-5p can provide a promising evaluation route in breast cancer prognosis. Furthermore, miR-342, miR-520 for triple negative and hormone receptor-positive types of breast cancer, respectively in collaboration with two detected distinct cluster of miRNAs for different breast cancer cell lines can be applied for more dedicated miRNA-based individualized targeted therapy. New DNA handling capacity of C-MYC-related oncogenic miRNAs through coordination with exosomal miRNAs and circulatory ones can be a potential appraisal tool in breast cancer management. Given the notion that genomic instability is a hallmark of breast cancer, the different horizons that are provided in this review can be employed for more precise and profound analyses to achieve an evaluation signature for breast cancer subtypes.
Insights
Disregulated C-MYC and microRNA (miRNA) profiles contribute to breast cancer heterogeneity. Specific miRNAs show promise for targeted therapy and prognosis in breast cancer subtypes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast cancer is a heterogeneous disease influenced by C-MYC and microRNA (miRNA) dysregulation.
- C-MYC acts as a master regulator, impacting numerous genes and cellular functions.
- miRNAs play critical roles in cellular behavior and are increasingly recognized in cancer development.
Purpose of the Study:
- To summarize recent advances in miRNA applications for breast cancer combinatorial targeted therapy.
- To highlight the prognostic potential of specific exosomal and circular miRNAs in breast cancer.
- To explore miRNA-based individualized targeted therapies for distinct breast cancer subtypes.
Main Methods:
- Review of recent literature on miRNA applications in breast cancer.
- Analysis of specific exosomal miRNAs (e.g., miR-126, miR-122) and circular miRNAs (e.g., miR-21-5p, miR-125b-5p) for prognostic value.
- Identification of miRNAs (e.g., miR-342, miR-520) for targeted therapy in triple-negative and hormone receptor-positive breast cancer.
Main Results:
- Certain exosomal and circular miRNAs offer promising avenues for breast cancer prognosis.
- Specific miRNAs, like miR-342 and miR-520, show potential for targeted therapy in distinct breast cancer types.
- C-MYC-related oncogenic miRNAs, in conjunction with exosomal and circulatory miRNAs, may serve as appraisal tools for breast cancer management.
Conclusions:
- miRNA profiles, in combination with C-MYC, are crucial in defining breast cancer subtypes.
- miRNAs represent a promising area for developing targeted therapies and improving prognostic assessments.
- Further research into miRNA signatures can lead to more precise analyses and personalized treatment strategies for breast cancer.
More Related Videos
09:06MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
09:45An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:23Abnormal Proliferation